Good to see you George and its a nice thread for new investors to know what the important catalyst are and how low the MC is for the developments that has happened in the last few years.
1. Since you are talking about Sarepta, I would say the most important catalyst would be results of P2B trial. Any results close to the Australia trial results and we are looking at immense rerate and valuation as we head to straight to commercialisation. There would be a direct comparison to the MC to Sarepta, irrespective of how long it will take ANP to actually start selling the drug .
2. LC partnering is another catalyst. Its interesting as we have the data and we have filed the patents, so anyone interested in know how their drug would work for LC , they need to partner and that means immediate $$ for further studies or more..
Any big name ( that are already selling Covid drug) with ANP will be a major event for us.
3. Point 2 is also applicable to LGMD . If the Dystro combo results are positive then again we talk about partnering interest.
All above ultimately opens up partnering possibilities, hence major catalyst as a few years of work has been done to get to the stage where we are now...
May be that's the reason , Anthony has been employed...
imo
ANP Price at posting:
9.0¢ Sentiment: Hold Disclosure: Held
